Cargando…

Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report

• Immune checkpoint inhibitors can be safely administered to patients with dermatomyositis. • Immunosuppressants did not impact the efficacy of treatment with an immune check point inhibitor. • Patients with autoimmune disorders who require immune check point inhibitors should be monitored by a rheu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valls, Maia L., Kase, Adam M., Patel, Rina, Wang, Benjamin, Aggarwal, Rohit, Colon-Otero, Gerardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156981/ https://www.ncbi.nlm.nih.gov/pubmed/35663849 http://dx.doi.org/10.1016/j.gore.2022.101010

Ejemplares similares

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Efficacy of gemcitabine in combination with nanoparticle albumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review
por: Kase, Adam M., et al.
Publicado: (2023)

MMR-deficiency and BRCA2/EGFR/NTRK mutations
por: Gokare, Prashanth, et al.
Publicado: (2017)

Lasting pathologic complete response to chemotherapy for ovarian cancer after receiving antimalarials for dermatomyositis
por: Cadena, Isabella, et al.
Publicado: (2018)

Case Report: Complete Response to Antiangiogenesis and Immune Checkpoint Blockade in an Unresectable MMR-Deficient Leiomyosarcoma Harboring Biallelic Loss of PTEN
por: Guo, Xi, et al.
Publicado: (2022)

A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin
por: Takatsuki, Kensaku, et al.
Publicado: (2021)

Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
por: Lin, Andy Yingjie, et al.
Publicado: (2015)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition
por: Zheng, Guoxing, et al.
Publicado: (2023)

Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I–III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol
por: Justesen, Tobias Freyberg, et al.
Publicado: (2023)

Improving health literacy with mumps, measles and rubella (MMR) vaccination: comparison of the readability of MMR patient-facing literature and MMR scientific abstracts
por: Downey, Tina, et al.
Publicado: (2022)

Mechanic’s Hand Heralding Relapse in an Indian Adolescent with Anti-MDA5 Positive Juvenile Dermatomyositis
por: Ganatra, Keya, et al.
Publicado: (2022)

MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation
por: Patel, Rutulkumar, et al.
Publicado: (2018)

COVID-19 vaccination outcomes among patients with dermatomyositis: a multicentered analysis
por: Pakhchanian, Haig, et al.
Publicado: (2022)

MMR Deficiency Defines Distinct Molecular Subtype of Breast Cancer with Histone Proteomic Networks
por: Hacking, Sean, et al.
Publicado: (2023)

Dermoscopy of Dermatomyositis in Dark Skin
por: Neema, Shekhar, et al.
Publicado: (2022)

Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
por: Marcrom, Samuel, et al.
Publicado: (2017)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
por: Fukuta, Kyotaro, et al.
Publicado: (2021)

Are pediatricians responsible for maintaining high MMR vaccination coverage? Nationwide survey on parental knowledge and attitudes towards MMR vaccine in Serbia
por: Loncarevic, Goranka S., et al.
Publicado: (2023)

Pathological complete response in MMR-deficient/MSI-high and KRAS-mutant patient with locally advanced rectal cancer after neoadjuvant chemoradiation with immunotherapy: A case report
por: Zhang, Mai, et al.
Publicado: (2022)

Pathological Complete Response Following Neoadjuvant Tislelizumab Monotherapy in Treatment-Naive Locally Advanced, MMR-Deficient/MSI-High Ascending Colon Cancer: A Case Report
por: Hei, Yue, et al.
Publicado: (2022)

MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
por: Fraune, Christoph, et al.
Publicado: (2020)

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
por: Su, Alan, et al.
Publicado: (2023)

Deep Learning Applied to Raman Spectroscopy for the Detection of Microsatellite Instability/MMR Deficient Colorectal Cancer
por: Blake, Nathan, et al.
Publicado: (2023)

Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma
por: Zibetti Dal Molin, Graziela, et al.
Publicado: (2018)

Anti-MDA-5 Dermatomyositis With Development of Drug-Mediated Necrolytic Skin Lesions
por: Case, Robert A., et al.
Publicado: (2020)

Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
por: Cheng, Hongyan, et al.
Publicado: (2019)

Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
por: Domingo-Musibay, Evidio, et al.
Publicado: (2018)

Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane
por: Alam, Walid, et al.
Publicado: (2021)

Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab
por: Kadota, Naoki, et al.
Publicado: (2021)

Complete Response of Triple-Negative Metaplastic Carcinoma of the Breast Using Pembrolizumab
por: Ladwa, Amrita, et al.
Publicado: (2023)

Challenges presented by complete response to immune checkpoint blockade in patients with dMMR colorectal cancer: A case report
por: Smith, Henry G., et al.
Publicado: (2023)

9. Hypomyopathic dermatomyositis complicated by mannose-binding lectin deficiency
por: Al-Attar, Mariam, et al.
Publicado: (2019)

SAT-454 Isolated ACTH Deficiency Due to Pembrolizumab
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2019)

Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas
por: Fraune, Christoph, et al.
Publicado: (2020)

Correction to: MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
por: Fraune, Christoph, et al.
Publicado: (2022)

Case Report: Life-threatening hypercalcemia associated with MMR-deficient endometrial carcinoma secreting parathyroid hormone
por: Liu, Huazhen, et al.
Publicado: (2023)

COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis
por: Pakhchanian, Haig, et al.
Publicado: (2022)

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system
por: Zhu, Chen, et al.
Publicado: (2023)

Immune response to second dose of MMR vaccine in Indian children
por: Gomber, Sunil, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_geqeu5cd8n4ehkbv7dc5hhmo86